Skip to content

Community-associated Highly-Resistant Enterobacterales

Community-associated Highly-Resistant Enterobacterales

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03924934
Acronym
COCARE
Enrollment
2172
Registered
2019-04-23
Start date
2019-05-01
Completion date
2024-12-01
Last updated
2025-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carbapenem-Resistant Enterobacteriaceae Infection, Community-Acquired Infections, Enterobacteriaceae Infections, Healthcare Associated Infection

Keywords

Infection, Bacterial Infection, CRE, Enterobacterales

Brief summary

This is a prospective multi-center study. Bacterial isolates from hospitalized patients with CA-HRE will be compared to those from hospitalized patients with healthcare-associated HRE (HA-HRE). In addition, community spread of CRE will be determined.

Detailed description

Patients who are discharged home from the hospital and meet criteria for possible CA-HRE will be recruited. These index participants will be interviewed to determine the epidemiologic network, and will be mailed a monthly BioWipe kit to screen for ongoing HRE intestinal carriage. Contacts of the index participant will also be approached and mailed a BioWipe kit to screen for the presence of HRE and/or carbapenemase gene(s) that were present in the index patient. If this initial sample is negative, the contact is not further interviewed or tested. If the initial screening is positive for the carbapenemase gene of interest, then the contact will be asked to answer the same questions as the index patient and will receive a monthly BioWipe kit. For each positive contact, a second-generation network of contacts will be constructed, who in turn will be approached for screening. An additional subset of participants, those with CDC-defined HRE isolated during hospitalization who are not discharged home will also be included. All HRE isolates that are isolated from the patient as part of routine clinical care will be sub-cultured and shipped to the central research laboratory. A limited data set will be collected.

Interventions

None listed

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)
CollaboratorNIH
University of North Carolina, Chapel Hill
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

Category 1: Patients who live at home and meet the following criteria: * CDC-defined HRE isolated during a previous hospitalization or outpatient visit * Home origin * First positive HRE culture within 48 hours of admission (in case of hospitalization) Category 2: Hospitalized patients with CDC-defined HRE isolated during hospitalization who are not discharged home and who meet any of the following criteria: * Admitted from other care facility (not home origin) * Do not have first positive HRE culture within 48 hours of admission Category 3: Patients with CDC-defined HRE isolated during a previous hospitalization or outpatient visit who are eventually discharged home and who meet any of the following criteria: * Admitted from other care facility (not home origin) * Do not have first positive HRE culture within 48 hours of admission (in case of hospitalization) Category 4: Participants who meet the following criteria: • Community contact of a participant in Category 1 and/or 3.

Exclusion criteria

In all categories, participants who meet the following criteria will be excluded: • Age \<18 years In category 1, the following are exclusionary: * pre-existing renal failure * pre-existing liver disease * immunocompromised * history of malignancy * pregnancy In addition, in category 1, 3 and 4, who meet the following criteria will be excluded: • Unable to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Proportion of CA-HRE infectionsenrollment - end of study, up to approximately 1 yearProportion of HRE cases diagnosed in hospitalized patients that are community-associated out of all CRE cases in hospitalized patients
Proportion of HRE-culture positive community contacts of hospitalized patients with HRE as determined by stool culture.enrollment - end of study, up to approximately 1 yearIn community contacts of patients discharged from the hospital after HRE diagnosis, the presence or absence of HRE in stool samples will be determined by culture. Then, the total number of community contacts with HRE-positive stool cultures will be divided by the total number of tested community contacts to derive the proportion of community contacts with stool cultures positive for HRE.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026